scholarly journals Serum Levels of Three Angiogenic Factors in Systemic Lupus Erythematosus and Their Clinical Significance

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Ling Zhou ◽  
Guoyuan Lu ◽  
Lei Shen ◽  
Linfeng Wang ◽  
Mingjun Wang
Keyword(s):  
Growth Factor ◽  
Lupus Erythematosus ◽  
Serum Levels ◽  
Angiogenic Factors ◽  
Vascular Endothelial ◽  
Healthy Controls ◽  
Placenta Growth Factor ◽  
Sledai Score ◽  
Endothelial Growth Factor ◽  
Normal Controls

Our research investigates the serum levels of three angiogenic factors in the AF family, namely, placenta growth factor (PlGF), basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (VEGF), in 54 patients with SLE (SLE group) and 28 healthy controls (normal control) through ELISA measurement. And their interrelationships were also systematically analyzed. The SLE patients were then divided into active SLE group and inactive SLE group according to the SLEDAI score. The results show that serum levels of PlGF, bFGF, and VEGF in all SLE group and active SLE group were higher than those in normal controls. Serum levels of PlGF and bFGF in inactive SLE group were higher than those in normal controls. The level of PlGF was positively correlated with VEGF in SLE patients and positive correlation is also shown in bFGF with VEGF. The levels of PlGF and VEGF in SLE patients were positively correlated with both ESR and SLEDAI score. Thus a tentative conclusion can be drawn that the serum levels of the angiogenic factors, for example, PlGF, bFGF, and VEGF, may be relevant in the pathogenesis of SLE, and the concentrations of PlGF and VEGF seem to be the markers of SLE activity.

scholarly journals Female sexual dysfunction in systemic sclerosis: The role of endothelial growth factor and endostatin

2018 ◽  
Vol 4 (1) ◽  
pp. 71-76 ◽  
Author(s):  
Antonietta Gigante ◽  
Luca Navarini ◽  
Domenico Margiotta ◽  
Biagio Barbano ◽  
Antonella Afeltra ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Blood Flow ◽  
Systemic Sclerosis ◽  
Growth Factor ◽  
Sexual Dysfunction ◽  
Resistive Index ◽  
Serum Levels ◽  
Vascular Endothelial ◽  
Healthy Controls ◽  
Endothelial Growth Factor

Introduction: Since female sexual dysfunction in systemic sclerosis women is multifactorial, we can assume that vascular damage may play a role in pathogenesis. The aim of the study was to evaluate the clitoral blood flow, by Echo color Doppler, and to correlate it whit serum levels of vascular endothelial growth factor and endostatin. Methods: A total of 15 systemic sclerosis women and 10 healthy controls matched for sex and age were enrolled in this study. Serum VEGF165 and endostatin levels were determined in systemic sclerosis patients by commercial enzyme-linked immunosorbent assay kit. Clitoral blood flow was measured by Doppler indices of clitoral artery: pulsatile index, resistive index, and systolic/diastolic ratio were measured. Sexual dysfunction was assessed by Female Sexual Function Index. Results: Vascular endothelial growth factor (pg/mL) and endostatin (ng/mL) median values were significantly higher in systemic sclerosis women than healthy controls. Resistive index and systolic/diastolic ratio median values were significantly higher in systemic sclerosis women than healthy controls. Negative correlation exists between serum levels of vascular endothelial growth factor and resistive index (r = −0.55, p < 0.05). Positive correlation was observed between serum levels of endostatin and resistive index (r = 0.70, p < 0.01) and systolic/diastolic ratio (r = 0.77, p < 0.01). Discussion: We can suppose that clitoral blood flow in systemic sclerosis women is reduced not only for macro- and microvascular damage but also for impaired angiogenesis.

Serum Levels of Vascular Endothelial Growth Factor (VEGF) and Basic Fibroblast Growth Factor (bFGF) in Children with Acute Lymphoblastic Leukemia.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4387-4387
Author(s):  
Izabela Palgan ◽  
Mariusz Wysocki ◽  
Krzysztof Palgan ◽  
Robert Debski ◽  
Grazyna Odrowaz-Sypniewska ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Lymphoblastic Leukemia ◽  
Serum Levels ◽  
Control Group ◽  
Vascular Endothelial ◽  
Healthy Controls ◽  
Fibroblast Growth ◽  
Childhood All ◽  
Endothelial Growth Factor

Abstract Angiogenesis is a process of blood vessel formation from the preexisting capillaries. It plays an essential role of growth and development of cancer. The aim of this study was to evaluate serum levels of the most important angiogenic stimulators, Vascular Endothelial Growth Factor (VEGF) and basic Fibroblast Growth Factor (bFGF) in children with acute lymphoblastic leukemia (ALL) and their relation to clinical manifestations of the disease, and in healthy controls. Although VEGF and bFGF have been suggested to be reliable prognostic indicators and important tools for treatment approach in hematopoietic malignancies and solid tumors, experience in childhood ALL has been limited. Patients and methods: 46 children with ALL (24 male, 22 female) aged 2-18 years (median 8 years) at the time of diagnosis and in remission and 70 healthy children (31 male, 39 female). For the quantitative determination of human VEGF and bFGF, the Quantikine (R&D Systems, Minneapolis, MN, USA), a solid phase enzyme-linked immunosorbent assay method was used. Elevated VEGF and bFGF were defined as being higher than the 95 percentile value in control group. Results: The range of VEGF serum levels in healthy controls was 24.73–467.7 pg/ml (median 168.9 pg/ml), 95 percentile was 431.85 pg/ml and the range of bFGF serum levels was 0–10.8 pg/ml (median 2.9 pg/ml), 95 percentile was 6.95 pg/ml. In children with ALL, the range of VEGF serum levels at the time of diagnosis was 0–532.3 pg/ml (median 91.18 pg/ml), and bFGF 0–64.48 pg/ml (median 5.11 pg/ml). In children in remission, the range of serum levels of VEGF was 53.15–962.67 pg/ml (median 209.73 pg/ml), and bFGF 0–32.5 pg/ml (median 5.98 pg/ml). The median level of VEGF at diagnosis was lower than those of the control group (p=0.006), and higher in remission, when compared to values obtained in children on diagnosis and in the control group (p=0.0005; p=0.01). Elevated level of VEGF was observed in 8.7% children at the time of diagnosis and in 24.4% of patients in remission. The median levels of bFGF at diagnosis and in remission were significantly higher than those in control group with 40% of children having elevated levels. A positive correlation between VEGF serum concentration and platelet number, and negative correlation between VEGF serum levels and WBC were observed, with no other correlations between growth factors (VEGF, bFGF) and age, type of lymphoblasts (FAB), risk group, and drug resistance. Conclusion: These results suggest that bFGF more than VEGF can play an important role in childhood ALL. The serum levels of angiogenic factors may be related to the activity of the disease, while both growth factors can possibly be a target of anti-angiogenic therapy.

Angiogenic Cytokines: Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Levels in Serum of Children with Hematopoietic Malignancies and Solid Tumors.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 3905-3905
Author(s):  
Izabela Palgan ◽  
Mariusz Wysocki ◽  
Krzysztof Palgan ◽  
Robert Debski ◽  
Jan Styczynski
Keyword(s):  
Growth Factor ◽  
Solid Tumors ◽  
Hematological Malignancies ◽  
Serum Levels ◽  
Control Group ◽  
Vascular Endothelial ◽  
Healthy Controls ◽  
Fibroblast Growth ◽  
Hematopoietic Malignancies ◽  
Endothelial Growth Factor

Abstract Angiogenesis is a process of blood vessel formation from the preexisting capillaries. It plays an essential role of growth and development of cancer. The most important angiogenic stimulators are Vascular Endothelial Growth Factor (VEGF) and basic Fibroblast Growth Factor (bFGF). The aim of the study was to evaluate the serum levels of VEGF and bFGF in children with solid tumors, hematological malignancies and in healthy controls. Patients: 110 children (33 with solid tumors and 77 with hematological malignancies, including 46 with acute lymphoblastic leukemia and 17 with acute myeloblastic leukemia) (56 male and 54 female) aged 2–18 years (median 8.5 years) and 70 healthy controls (31 male and 39 female) aged 3–18 years (median 13 years). For the quantitative determination the Quantikine VEGF and bFGF immunoassay, a solid-phase enzyme-linked immunosorbent assay method was used. Elevated VEGF and bFGF were defined as being higher than the 95 percentile value in control group. Results: At the time of diagnosis the range of VEGF serum levels in all cancer patiens was 0–2691.3 pg/ml, and in remission 6.08–967.67 pg/ml; while the range of bFGF at diagnosis was 0–64.48 pg/ml, and in remission 0–32.52 pg/ml. In all children with cancer, serum levels of VEGF and bFGF were significantly more often elevated than in healthy controls (p<0.004; p<0.0005). At diagnosis, almost 12% patients had simultaneously elevated serum levels of VEGF and bFGF. Among patients with solid tumors at the time of diagnosis, elevated levels of VEGF and bFGF was observed in 42% and 60%, respectively. There were no differences between serum levels of these factors in patients in remission and in control group. In patients with progression, serum levels of VEGF and bFGF were higher, when compared to levels of these factors at diagnosis. The range of serum levels of VEGF in children with solid tumors at the time of diagnosis was 85.96–2691.3 pg/ml (median 365.48 pg/ml), and in remission 6.08–787.16 pg/ml (median 204.1 pg/ml). The median level of VEGF at diagnosis in children with hematopoietic malignancies (range 0–1869.6 pg/ml, median 111.6 pg/ml) was lower than in children with solid tumors (p<0.0005). In children with acute leukemias at diagnosis, serum levels of VEGF were significantly lower than in children with lymphomas (p<0.0003) and in controls (p<0.05). These results suggest that evaluation of serum levels of VEGF and bFGF can be helpful for monitoring activity of cancer, particularly in solid tumors and in the future can be a target of anti-angiogenic therapy.

Elevated Endothelial Progenitor Cells during Painful Sickle Cell Crisis

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4796-4796
Author(s):  
Erfan Nur ◽  
Rachel T. van Beem ◽  
Jaap Jan Zwaginga ◽  
Precious Landburg ◽  
Eduard J. van Beers ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Steady State ◽  
Growth Factor ◽  
Sickle Cell ◽  
Serum Levels ◽  
Vascular Endothelial ◽  
Healthy Controls ◽  
Sickle Cell Crisis ◽  
Endothelial Growth Factor ◽  
Painful Crisis

Abstract Background: Sickle Cell Disease (SCD) is characterized by microvascular occlusion leading to an ischemia-induced pro-angiogenic response. Circulating endothelial progenitor cells (EPCs) play an important role in neovascularisation and decreased EPC numbers are associated with poor outcome in cardiovascular disease. Aims: To determine the numbers of circulating EPCs in patients with SCD during steady state and painful crisis and to assess the association of EPC numbers with serum levels of humoral growth factors (stromal derived growth factor-1α (SDF-1α), erythropoietin (EPO), vascular endothelial growth factor (VEGF), placenta-induced growth factor (PIGF), interleuking-8 (IL-8), soluble vascular adhesion molecule-1 (sVCAM-1)). Methods: Numbers of circulating EPCs, defined as CD45dim/CD34+ cells expressing vascular endothelial growth factor receptor-2 (VEGF-R2), and serum levels of humoral factors were measured consecutively in 66 patients in steady state, 23 patients during painful sickle cell crisis and 13 age- and race-matched healthy controls. Results: While circulating EPC numbers were comparable between healthy controls and sickle cell patients in steady state, they were significantly increased in patients during sickle cell crisis. EPC numbers correlated significantly only to serum SDF-1α levels during painful crisis. Conclusion: Sickle cell crisis is characterized by elevated circulating EPC numbers further supporting a pro-angiogenic state in SCD. SDF-1 may play a role of importance in EPC mobilisation during sickle cell crisis.

Sign in / Sign up

Export Citation Format

Share Document